H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Nemaura Medical to $7 from $8 and keeps a Buy rating on the shares post the fiscal Q3 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
- Nemaura Medical reports Q3 EPS (7c), consensus (18c)
- Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
- Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
- Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement